Tirzepatide ���子背景与靶点 — Background and Details

By Editorial Desk · published 2026-04-08 · last reviewed 2026-05-30 · Blog

The short version of albumin binding fits in a sentence. The long version — which is the one that helps — is below.

Reviewed 2026-05-30. Anything still debated is marked as such rather than presented as settled.

Tirzepatide 分子背景与靶点

当前公开资料把 tirzepatide 归为肠促胰素类受体双重激动剂。它并非激素天然变体，而是经过序列改造的工程化肽。其分子量、等电点与疏水性等基础参数已在药典和化学数据库中收录，可作为分析检测和质量研究的参照。

Tirzepatide 是一种由 39 个氨基酸组成的合成肽，分子结构上以 GIP 序列为骨架并引入脂肪酸侧链修饰，使其能够同时与葡萄糖依赖性促胰岛素多肽（GIP）受体和胰高血糖素样肽-1（GLP-1）受体结合。这种双重激动特性使它在同类肽类药物中区别于选择性 GLP-1 受体激动剂。该分子最早由一家制药公司在 2010 年代报道，随后进入糖尿病与体重管理领域的临床研究。

Dual Incretin Receptor Pharmacology

Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.

Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.

At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.

Tirzepatide at a glance

Molecular Background and Dual Receptor Action

Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.

Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.

Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.

Related pages on this site

• Smart toolkit
• Focused checklist
• Optimized primer
• Focused collection
• Quality summary
• Adaptive archive
• Regional toolkit
• Proven handbook

Tirzepatide Pharmacology and Development History

The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.

Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.

Molecular Background and Receptor Pharmacology

The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.

After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.

Reference notes

=== Mass photometry === Mass photometry (MP) is a rapid, in-solution, label-free method of obtaining the molecular mass of proteins, lipids, sugars and nucleic acids at the single-molecule level. The technique is based on interferometric scattered light microscopy. Contrast from scattered light by a single binding event at the interface between the protein solution and glass slide is detected and is linearly proportional to the mass of the molecule. This technique can also be used to measure sample homogeneity, to detect protein oligomerisation states, and to identify complex macromolecular assemblies (ribosomes, GroEL, AAV) and protein interactions such as protein-protein interactions. Mass photometry can accurately measure molecular mass over a wide range of molecular masses (40 kDa – 5 MDa).

=== Pharmacokinetics === Metribolone has very low affinity for human serum sex hormone-binding globulin (SHBG), less than 5% of that of testosterone and less than 1% of that of dihydrotestosterone (DHT).

==== Cytosine deamination increases C-To-T mutations ==== A known result of cytosine methylation is the increase of C-to-T transition mutations through the process of deamination. Cytosine deamination can alter the genome's many regulatory functions; previously silenced transposable elements (TEs) may become transcriptionally active due to the loss of CPG sites. TEs have been proposed to accelerate the mechanism of enhancer creation by providing extra DNA that is compatible with the host transcription factors that eventually have an impact on C-to-T mutations.

The video for "Man in the Box" would go on to be nominated for an MTV Video Music Award for Best Rock Video in that month, and a nomination for the Grammy Award for Grammy Award for Best Hard Rock Performance with Vocal followed a few months later. Despite their success, lead vocalist Layne Staley and bassist Mike Starr were both introduced to heroin during the Van Halen tour, which would go on to shape not only their personal lives but also the band's creative direction.

== Mechanism of action == Levosimendan is a calcium sensitizer — it increases the sensitivity of the heart to calcium, thus increasing cardiac contractility without a rise in intracellular calcium. Levosimendan exerts its positive inotropic effect by increasing calcium sensitivity of myocytes by binding to cardiac troponin C in a calcium-dependent manner. It also has a vasodilatory effect, by opening adenosine triphosphate (ATP)-sensitive potassium channels in vascular smooth muscle to cause smooth muscle relaxation. The combined inotropic and vasodilatory actions result in an increased force of contraction, decreased preload and decreased afterload. Moreover, by opening also the mitochondrial (ATP)-sensitive potassium channels in cardiomyocytes, the drug exerts a cardioprotective effect.

Sources: en.wikipedia.org

Notes from published material

Among the many varieties of microorganisms, relatively few cause disease in otherwise healthy individuals. Infectious disease results from the interplay between those few pathogens and the defenses of the hosts they infect. The appearance and severity of disease resulting from any pathogen depend upon the ability of that pathogen to damage the host as well as the ability of the host to resist the pathogen. However, a host's immune system can also cause damage to the host itself in an attempt to control the infection. Clinicians, therefore, classify infectious microorganisms or microbes according to the status of host defenses – either as primary pathogens or as opportunistic pathogens.

=== British republicanism === Hitchens was a vocal supporter of republicanism in the United Kingdom, advocating the abolition of the monarchy, and in 1990 published the book-long polemic The Monarchy: A Critique of Britain's Favourite Fetish. His 1998 documentary Princess Diana: The Mourning After accused the British media of playing an essential role in creating a national, unchallengeable, and at times hysterical cult of personality surrounding the death of Diana, Princess of Wales, whereas previously they had been extremely critical of her and the monarchy after she had separated and divorced from Charles, Prince of Wales, and was having an affair with Egyptian billionaire Dodi Fayed. Hitchens claimed the public were behaving irrationally, and that many appeared to not even know why they were mourning. He also scrutinised the level of censorship against criticism of Diana and the monarchy but was accused, in a review by The Independent, of exaggerating on this point.

The 2002 study concluded that "the theory TT possesses is deprived of explanatory power" and "evidence that supports the current picture of physical energy should be regarded as evidence against the theory of TT". The supposed healing in TT takes place through a discredited physical process called "electron transfer resonance", which the physicist Alan Sokal describes as "nonsense."

=== Reunion: 2007–present === The Jesus and Mary Chain reunited to perform at Coachella on 27 April 2007. During "Just Like Honey", Scarlett Johansson, who starred in the film Lost in Translation featuring the song, performed with the band on the main stage. The band held a warm-up gig the day before in Pomona, California with Giant Drag's Annie Hardy as the guest. The band's first UK performance since reforming was at the Meltdown festival in June. In June 2007, Jim Reid revealed that the band was working on a new album. In March 2008, the band released "All Things Must Pass" for the soundtrack to NBC's television series Heroes, their first new song since 1998. In September 2008, Rhino Records released the 4-CD compilation The Power of Negative Thinking: B-Sides & Rarities. In 2010, a greatest hits album, Upside Down: The Best of The Jesus and Mary Chain, was released via Music Club Deluxe. The band toured North America in 2012 and also played China for the first time in May. The lineup featured guitarist John Moore and Fountains of Wayne drummer Brian Young replacing Loz Colbert. Mark Crozer replaced Moore beginning with the band's Tel Aviv shows in October. In 2013, it was announced that a full-discography vinyl box set, dubbed as The Complete Vinyl Collection, would be released for the band's 30th anniversary, via Demon Music Group. In 2014, the band became the first to sign to the newly reformed Creation Management, helmed by Alan McGee. The band played Psychocandy in full through 2015 to celebrate the album's 30th anniversary.

Sources: en.wikipedia.org

Frequently asked questions